Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 996,114 shares of the company’s stock, valued at approximately $10,927,000. Connor Clark & Lunn Investment Management Ltd. owned about 1.12% of Kura Oncology as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of the stock. BlackRock Inc. bought a new position in Kura Oncology during the second quarter valued at $115,286,000. State Street Corp raised its stake in shares of Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after buying an additional 1,587,959 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in shares of Kura Oncology by 101.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after buying an additional 1,121,228 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Kura Oncology by 111.6% during the 4th quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock worth $19,020,000 after acquiring an additional 965,256 shares during the period. Finally, AQR Capital Management LLC increased its holdings in Kura Oncology by 36.6% in the 4th quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after acquiring an additional 820,020 shares during the last quarter.
Insider Activity
In related news, insider Mollie Leoni sold 84,929 shares of Kura Oncology stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the sale, the insider owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Troy Edward Wilson bought 100,000 shares of Kura Oncology stock in a transaction that occurred on Monday, August 24th. The shares were acquired at an average price of $12.39 per share, with a total value of $1,239,000.00. Following the completion of the transaction, the chief executive officer owned 479,194 shares of the company’s stock, valued at $5,937,213.66. This represents a 26.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have sold 120,761 shares of company stock valued at $1,283,346. 7.60% of the stock is owned by company insiders.
Kura Oncology Trading Down 3.9%
Kura Oncology (NASDAQ:KURA – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. The company had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. On average, equities analysts forecast that Kura Oncology, Inc. will post -3.23 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on the company. Jefferies Financial Group set a $24.00 price objective on Kura Oncology in a research note on Thursday, May 28th. Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a research note on Monday. Oppenheimer set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, May 28th. Wedbush upped their price target on shares of Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Finally, Raymond James Financial set a $24.00 price target on shares of Kura Oncology in a research note on Monday. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.40.
View Our Latest Research Report on KURA
Key Headlines Impacting Kura Oncology
Here are the key news stories impacting Kura Oncology this week:
- Positive Sentiment: CEO Troy Wilson reportedly purchased 100,000 shares for approximately $1.24 million, a sizable open-market investment that investors may interpret as confidence in Kura’s growth prospects. Kura Oncology shares jump after CEO buys $1.24 million of stock
- Positive Sentiment: Analysts continue to express optimism, with Citizens JMP reiterating a “Market Outperform” rating. Broader coverage shows a consensus “Moderate Buy” rating and an average price target of $25.40, materially above recent trading levels. Citizens JMP reiterates Market Outperform rating
- Positive Sentiment: Kura’s commercial outlook is being supported by KOMZIFTI (ziftomenib), which generated $9.1 million in net product revenue over its first two quarters, including 57% sequential growth. Potential expansion into first-line acute myeloid leukemia could substantially increase the addressable market. Phase 1b data are expected in the second half of 2026, with Phase 3 KOMET-017 topline results targeted for 2028. Kura Oncology: Strong Buy and ziftomenib AML expansion prospects
- Positive Sentiment: Recent earnings exceeded expectations: quarterly revenue was $20.87 million versus a $20.16 million consensus estimate, while the per-share loss was narrower than forecast. Institutional ownership also increased, including a large position expansion by California State Teachers’ Retirement System.
- Neutral Sentiment: The company remains unprofitable, with analysts expecting a full-year loss, so valuation remains dependent on continued KOMZIFTI sales growth and successful clinical development.
- Negative Sentiment: Insider Brian Powl sold 4,345 shares worth approximately $51,662. The sale was relatively small and reduced his holdings by 2.5%, but it contrasts with the CEO’s much larger purchase. Kura Oncology insider share sale
Kura Oncology Company Profile
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Read More
- Five stocks we like better than Kura Oncology
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
